| Publication | Population | EULAR/ACR criteria | Arthritis controls | ANA positive | |
|---|---|---|---|---|---|
| Sensitivity | Specificity | ||||
| Adamichou et al 2019 | Early SLE | 88.6% | 97.3% | 37.2% | 93.6% |
| Aljaberi et al 2020 | Pediatric SLE | 84.8% | 82.8% * | 35% | 96% |
| Aringer et al 2019 (1,2)(validation) | SLE | 96.1% | 93.4% | --- | 99.3% |
| Aringer et al (derivation) | SLE | 98.% | 96% | --- | 99.6% |
| Batu et al 2020 | Pediatric SLE | 91.6% | 88.5% * | 41.4% | 98.9% |
| Dahlström & Sjöwall 2019 | SLE | 93% | 73%* | 38.2% | 98.2% |
| Gegenava et al 2019 | NPSLE | 87% | 74% | 16.7% | 96.3% |
| Lee et al 2020 | SLE | 97.6% | 91.4% * | 31.2% | 98.8% |
| Levinsky et al 2021 | Pediatric SLE | 96% | 89%* | 35.4% | 100% |
| Ma et al 2020 | Pediatric SLE | 97.4% | 98.4% | 58% | 100% |
| Petri et al 2020 | SLE | 90.8% | 88.6% * | 33.4% | 97.7% |
| Rodrigues Fonseca et al 2019 (BL) | Pediatric SLE | 89.3% | 67.4% * | 66.3% | NR |
| Rodrigues Fonseca et al (one year) | Pediatric SLE | 95.1% | 58.4% * | 73% | NR |
| Rubio et al 2020 | SLE | 94.9% | NA | NA | 96.3% |
| Smith et al 2021 | Pediatric SLE | 94% | 77%* | 23.3% | 93.1% |
| Suda et al | SLE | 92% | NA | NA | 92% |
| Teng et al 2020 | SLE | 96.5% | 90.3% * | 39% | 99.5% |
| Wang et al 2021 | LN | 95.2% | NA | 37.2% | 95.2% |
| Whittall Garcia et al 2021 | SLE | 95.7% | NA | 35% | 97.1% |
Arthritis controls: % non-SLE control population with joint diseases, NR not reported, NA not applicable, * included into specificity analysis. LN lupus nephritis.